Drug Profile
TKB 662
Alternative Names: TKB-662Latest Information Update: 27 Sep 2013
Price :
$50
*
At a glance
- Originator Isotechnika
- Class
- Mechanism of Action Lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 27 Sep 2013 Discontinued - Preclinical for Transplant rejection in Canada (unspecified route)
- 31 Dec 2006 No development reported - Preclinical for Transplant rejection in Canada (unspecified route)
- 05 Nov 2004 TKB 662 is available for licensing (http://www.isotechnika.com)